OAE Publishing Inc. Reviews Electrochemical Immunosensor Advances for Cardiovascular Biomarker Detection, Achieving Ultra-Low 1.56 pg/mL Detection Limit

OAE Publishing Inc. China

Overview

OAE Publishing Inc. has published a review on the latest advancements in electrochemical immunosensors for cardiovascular biomarker detection. The review highlights non-specific adsorption and biofouling in complex biofluids as critical challenges for practical application. However, electrochemical immunosensors based on gold nanoparticles supported by conductive conjugated polymers have achieved an ultra-low detection limit of 1.56 pg/mL, demonstrating excellent selectivity, reproducibility, and long-term stability. This underscores the significant potential for highly sensitive and portable detection in early screening and diagnosis of cardiovascular diseases.

In Depth

Key Findings

OAE Publishing Inc. has released a comprehensive review detailing the latest advancements in electrochemical immunosensors specifically for the detection of cardiovascular disease (CVD)-related biomarkers. The review explicitly identifies non-specific adsorption and biofouling in complex biological fluids as a major impediment to the practical implementation of electrochemical immunosensors. Nevertheless, it highlights that novel electrochemical immunosensors based on gold nanoparticles supported by conductive conjugated polymers have achieved an extremely low detection limit of just 1.56 pg/mL, while simultaneously exhibiting superior selectivity, reproducibility, and long-term stability. This breakthrough underscores the immense potential for highly sensitive detection in the early screening and auxiliary diagnosis of CVDs.

Technical and Clinical Details

Electrochemical immunosensors leverage the specificity of antigen-antibody reactions, converting binding events into electrical signals. Compared to traditional detection methods, they offer advantages in ease of operation, rapid response times, and portability. The technologies highlighted in the review often employ composite materials of conductive conjugated polymers (e.g., polyaniline, PEDOT:PSS) and gold nanoparticles (AuNPs) as the sensor platform. AuNPs, due to their high conductivity, large surface area, and biocompatibility, enhance antibody immobilization efficiency and amplify electrochemical signals. Furthermore, the conductive conjugated polymers provide excellent antifouling properties, suppressing non-specific adsorption of non-target molecules present in complex biological fluids like plasma or serum, thereby improving sensor stability and specificity. This enables highly sensitive and accurate detection of CVD biomarkers such as C-reactive protein (CRP) and low-density lipoprotein (LDL).

Background and Industry Context

Cardiovascular diseases remain a leading cause of death worldwide, making their early detection and risk assessment a critical public health priority. Many existing CVD diagnostic methods are often expensive, require specialized expertise, and tend to be time-consuming. Electrochemical immunosensors hold the potential to overcome these challenges, offering low-cost, rapid diagnostic solutions particularly suited for Point-of-Care Testing (POCT) and home-based self-monitoring. The issues of non-specific adsorption and biofouling have been long-standing bottlenecks in the practical application of sensors using biological samples, but advances in antifouling materials and nanotechnology are leading to effective solutions.Strategic Significance and Outlook

The advancements in electrochemical immunosensors outlined in this review hold the potential to revolutionize CVD diagnosis. Future developments are expected to include the creation of multiplex sensors capable of simultaneously detecting multiple CVD biomarkers, further miniaturization, and integration into wearable devices. In conjunction with AI and IoT technologies, real-time analysis of sensor data can lead to intelligent healthcare systems that assess individual patient risks and provide personalized preventive and therapeutic strategies. These technologies will be essential tools for improving the accuracy and efficiency of CVD prevention, early diagnosis, and treatment monitoring, ultimately enhancing patient outcomes.